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Abstract
Background: The recent discovery of cell cycle arrest biomarkers, tissue inhibitor of
metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein 7 (IGFBP7),
has led to a newly available clinical test for acute kidney injury. The performance of
these markers in preclinical studies has not been established. Therefore, we sought
to evaluate the performance of TIMP-2 and IGFBP7 in rats undergoing cecal ligation
and puncture.
Methods: In this secondary analysis, we analyzed banked urine samples from
60 Sprague-Dawley rats undergoing cecal ligation and puncture (CLP). Samples
were obtained from baseline, 18 h after CLP, at the end of fluid resuscitation
(22 h after CLP), and again 24 h later. We measured TIMP-2 and IGFBP7 and
compared the results to acute kidney injury by RIFLE criteria for creatinine using
area under the receiver operating characteristic curve (AUC). The primary endpoint was
moderate-to-severe acute kidney injury (AKI) (I or F criteria), and the primary time point
was immediately after fluid resuscitation. Secondary outcomes included mortality and
comparisons with other biomarkers: cystatin C and neutrophil gelatinase-associated
lipocalin (NGAL) in both urine and plasma.
Results: After fluid resuscitation, urine [TIMP-2] and [IGFBP7] were significantly
higher in animals developing moderate-to-severe AKI (p = 0.002 and p = 0.01).
AUC of [TIMP-2]·[IGFBP7] for AKI was 0.89 (95 % CI 0.80–0.98). By contrast,
the next best AUC was seen with plasma cystatin C (0.78; 95 % CI 0.65–0.90).
[TIMP-2]·[IGFBP7] also predicted mortality (AUC 0.69; 95 % CI 0.53–0.85).
Conclusions: In this experimental model of sepsis in the rat, cell cycle arrest
biomarkers TIMP-2 and IGFBP7 are valid predictors of acute kidney injury.
Keywords: Acute kidney injury, Sepsis, Tissue inhibitor of metalloproteinases
(TIMP)-2, Insulin-like growth factor binding protein 7 (IGFBP7), Cell cycle arrest,
Biomarkers
Background
Recently, two novel urinary biomarkers, tissue inhibitor of metalloproteinases-2 (TIMP-2)
and insulin-like growth factor-binding protein 7 (IGFBP7), were validated for predicting
moderate-to-severe acute kidney injury (AKI) (stages 2 and 3 by Kidney Disease Improving
Global Outcome (KDIGO) [1] criteria) in critically ill patients [2, 3]. Both TIMP-2 and
IGFBP7 are markers of G1 cell-cycle arrest, which prevents cells from dividing when
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potentially injured [4], and both appear to respond to a wide variety of cellular stressors
including inflammation, ischemia, oxidative stress, drugs, and toxins [5–7]. Furthermore,
both molecules also act as “alarm” proteins exerting paracrine effects on adjacent cells [8].
Novel AKI biomarkers may play important roles clinically [9], but they also have great
potential to transform clinical trials [10, 11]. As such, it is important to understand how
these markers perform in preclinical models of AKI. Sepsis is the most common cause of
AKI in critically ill patients [12, 13], and cecal ligation and puncture (CLP) in small animals
is a commonly used preclinical model.
Thus, we sought to evaluate the performance of [TIMP-2]·[IGFBP7] in an rat model
of sepsis. In order to be consistent with the human trials that were used to discover
and validate these biomarkers [2, 3], we used moderate-to-severe AKI (equivalent to
KDIGO stages 2–3 or RIFLE I-F) as the primary outcome. We assessed biomarker
performance at various time points, but we used the immediate post-resuscitation time
point as primary because it most closely matches the time when patients were enrolled
in these trials.
Methods
For this analysis, we used banked samples from 60 animals used in a prior laboratory
experiment involving rats subject to cecal ligation and puncture and randomized to
resuscitation with two different crystalloids: 0.9 % saline and plasmalyte. Complete
details of the parent study have been published [14]. Briefly, 24- to 28-week-old (weight
400–600 g) male, Sprague-Dawley rats were anesthetized with intraperitoneal injection
of pentobarbital sodium (50 mg/kg) and subjected to CLP with a predetermined 25 %
ligated length of cecum and 18-gauge needle: two punctures inferior to the ileocecal
valve. Eighteen hours after CLP animals were re-anesthetized, vascular cannula were
placed and animals received 10 ml/kg fluid resuscitation in the first hour with either
0.9 % saline or plasmalyte. For the next 3 h, animals received the same fluid at 5 ml/kg/h.
Animals were observed for survival over an additional 24 h. Blood (1 ml) was drawn from
the arterial line, and urine (1–2 ml) was taken from the bladder at 0 (baseline), 18 (before
fluid resuscitation), 22 (end of fluid resuscitation), and 24 h after fluid resuscitation (46 h
after CLP). Isolated plasma and urine was kept at −80 °C for subsequent neutrophil
gelatinase-associated lipocalin (NGAL), cystatin C, and creatinine (Cr) measurements and
the remainder stored.
Plasma NGAL and urine NGAL were determined using ELISA (BioPorto Diagnostics,
Gentofte, Denmark). Plasma creatinine was detected with a creatinine enzymatic assay
kit (BioVision Technologies, Mountain View, CA). Plasma cystatin C and urine cystatin
C were measured by ELISA (BioVendor LLC, Candler, NC). Frozen urine samples were
used for measurement of TIMP-2 and IGFBP7 by ELISA. The ELISA for TIMP-2 was
made using capture and detect antibodies from R&D Systems (Minneapolis, MN) and
the ELISA for IGFBP7 using capture and detect antibodies from Thermo Fisher Scientific
(Waltham, MA) and R&D Systems, respectively. TIMP-2 and IGFBP7 protein from
Abcam (Cambridge, UK) and U-Protein Express (Utrecht, Netherlands), respectively, were
used for calibration. The calibration range for both assays was 0.0156 to 2 μg/mL.
We determined the severity of AKI using the serum creatinine portion of the RIFLE
criteria [15], which classified risk (R), injury (I), and failure (F), on the basis of
maximum creatinine increase of 150, 200, and 300 %, respectively, in the 2 days
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following CLP. For the primary analysis, we compared I and F to R and no AKI.
Biomarker data are expressed as means ± standard error (SE). Student’s t tests were
applied to compare means. Biomarker concentrations were compared across the first
three time points using repeated measures ANOVA with Huynh-Feldt correction. The
fourth time point was not included because only 19 rats had both TIMP-2 and IGFBP7
results for all four time points. Dunnett’s test was used for pairwise comparisons with
the baseline time point as the control. We calculated area under the receiver operator
characteristic curve (AUC) and 95 % confidence intervals [16]. Analyse-it (Analyse-it
Software, Ltd., UK) and XLSTAT (Addinsoft, Paris, France) software were used for
statistical analysis. A two-sided P < 0.05 was considered statistically significant.
Results
TIMP-2, IGFBP7, and AKI
Samples were available at 18 and 22 h (right before and after fluid resuscitation) from
48 animals. Of these, 30 developed RIFLE I/F (18 I and 12 F) and 18 either had no AKI
(8) or R (10). For animals developing AKI, creatinine peaked most often, at the 48-h
time point. Immediately after fluid resuscitation, 22 h after CLP, urine concentrations
of both TIMP-2 and IGFBP7 were greater in animals who ultimately manifested RIFLE
I/F compared to those who did not (Fig. 1). The AUC for [TIMP-2]·[IGFBP7] for AKI
was 0.89 (95 % CI 0.80–0.98). Interestingly, the AUCs for individual markers were
significantly (p < 0.05) lower than the composite (0.76 and 0.72 for TIMP-2 and
IGFBP7, respectively). There were no significant differences between the performance of
TIMP-2 and IGFBP7 in animals receiving saline or plasmalyte. Mean [TIMP-2]·[IGFBP7]
at 18 and 22 h were similar for animals receiving plasmaltye compared to saline (at 18 h
Fig. 1 Urinary [TIMP-2], [IGFPB7], or [TIMP-2]·[IGFPB7] levels from animals with no AKI (or only RIFLE R) (n = 18)
compared to RIFLE I or F (n = 30). Box and whiskers show interquartile range and 5th to 95th percentiles,
respectively. Horizontal dash shows the median, and X shows the mean. *P = 0.01, **P = 0.002, ***P < 0.001
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0.034 (95 % CI 0.023–0.046) vs. 0.028 (μg/ml)2 (95 % CI 0.017–0.039), p = 0.43 or at 22 h
0.034 (95 % CI 0.025–0.042) vs. 0.029 (μg/ml)2 (95 % CI 0.022–0.037), p = 0.43). However,
fewer animals developed the endpoint in the plasmalyte group as reported previously
[14]. At baseline, [TIMP-2]·[IGFBP7] results were not different between those animals
who ultimately developed AKI compared to those who did not (Fig. 2). Both TIMP-2 and
IGFBP7 increased 18 h after CLP compared to baseline (p = 0.01 and p < 0.0001,
respectively). However, neither [TIMP-2]·[IGFBP7] (Fig. 2) nor individual markers (data
not shown) discriminated well for AKI at the 18-h (pre-resuscitation) time point.
Comparison with other urine biomarkers
Performances for various AKI biomarkers are shown in Table 1. The same time point
(immediately after resuscitation) and same outcome, RIFLE I/F, were used for all
comparisons. The AUC for [TIMP-2]·[IGFBP7] was significantly greater than for urine
NGAL (0.89 vs. 0.71, P < 0.05) or plasma NGAL (0.89 vs. 0.62, P < 0.05; Table 1).
Mortality
Early mortality (prior to day 2 after CLP) was observed in 19 animals. All deaths exhibited
AKI. Immediately after fluid resuscitation, 22 h after CLP, urine concentrations of IGFBP7
(P = 0.002) but not TIMP-2 (P = 0.48) were greater in animals who died prior to day 2
compared to those who did not (Fig. 3). The AUC for [IGFBP7] alone was 0.76
(95 % CI 0.63–0.90) whereas the AUC for [TIMP-2]·[IGFBP7] for AKI was 0.69
(95 % CI 0.53–0.85).
Discussion
Prior animal studies have examined TIMP-2 in relation to AKI [17, 18], and several
studies have examined IGF binding proteins in renal disease [19] but none have directly
Fig. 2 Box-and-whisker plots for [TIMP-2]·[IGFPB7] at various time points comparing no AKI or RIFLE R versus
RIFLE I or F. ***p < 0.001 for immediately after fluid resuscitation
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determined the performance of [TIMP-2]·[IGFBP7] for the prediction of RIFLE I/F AKI
in an experimental model. Thus, to our knowledge, this is the first cross-species
validation of [TIMP-2]·[IGFBP7] for AKI and establishes the test as a viable tool in the
preclinical space. This is important because clinical trials that use [TIMP-2]·[IGFBP7]
for enrichment will benefit from preclinical data that closely matches the trial design.
For this reason, we designed this laboratory investigation to simulate the clinical
situation as much as possible. We used moderate-to-severe AKI (RIFLE I/F = KDIGO
2/3) as the endpoint, and we tested biomarkers at a time that closely mimics enrolment
in clinical trials as well as clinical use in general.
There were several unexpected results of our investigation. First, earlier measurement
of [TIMP-2]·[IGFBP7] (at 18 h after CLP and prior to fluids), while demonstrating an
increase compared to baseline, was not predictive of RIFLE I/F AKI. We speculate that
early increases in TIMP-2 and IGFBP7 might have been protective for some animals
while sustained elevations were consistently associated with development of AKI. This
result may help explain recent findings in humans where early release of TIMP-2 and
IGFBP7 was associated with the protection from AKI in the setting of remote ischemic
Table 1 Comparison of biomarkers for predicting RIFLE I/F
Biomarker No AKI AKI p value AUC
[TIMP-2]·[IGFBP7] (μg2/mL2) 0.019 ± 0.001 0.039 ± 0.003 <0.0001 0.89 (0.80–0.98)
Urine NGAL (IU/mL) 2157.6 ± 102.4 2472.8 ± 123 0.04 0.71 (0.63–0.80)
Plasma NGAL (IU/mL) 2143.3 ± 29.6 2077 ± 44.5 0.21 0.62 (0.46–0.79)
Urine cystatin C (IU/mL) 1609.8 ± 284.6 2572.8 ± 353.6 0.03 0.75 (0.56–0.93)
Plasma cystatin C (IU/mL) 1027.3 ± 185.8 2344.9 ± 462.5 <0.01 0.78 (0.65–0.90)
All comparisons are for the post-resuscitation (primary) time point. Shown are means ± standard error and areas under
the receiver operating characteristic curves (AUC) with 95 % confidence intervals. P values are for two-sided t test
Fig. 3 Urinary [TIMP-2], [IGFPB7], or [TIMP-2]·[IGFPB7] levels from animals that survived (n = 29) compared to
those that died (n = 19). Box and whiskers show interquartile range and 5th to 95th percentiles, respectively.
Horizontal dash shows the median, and X shows the mean. *P = 0.03, **P = 0.002
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preconditioning and subsequent cardiac surgery [11]. The mechanisms responsible for
this effect are still unclear, but we have proposed that limb ischemia releases damage-
associated molecular patterns that signal the kidney to release TIMP-2 and IGFBP7 as
part of an “alarm” that protects cells from subsequent injury [20]. Since temporary cell
cycle arrest is a protective mechanism, it is reasonable to expect that under certain
circumstances the mechanism works and release of TIMP-2 and IGFBP7 is not
followed by AKI [9]. We speculate that pre-resuscitation levels may identify “renal
stress” but not necessarily predict the effectiveness of the resuscitation. Whereas post-
resuscitation levels may be more predictive of the pathologic (as opposed to adaptive)
state. Alternatively, animals at pre-resuscitation may in fact already have renal injury
but it may still be reversible. For animals that responded to resuscitation, they rapidly
resolved this injury and no longer exhibited biomarker signatures nor did they manifest
clinical AKI. Further study will be necessary to test these hypotheses. However, the
finding does have implications for clinical trials and clinical care. For example, the test
may have less utility in the pre-hospital arena. Second, it may point to a need to retest
patients if clinical evaluation suggests that they were not resuscitated on initial testing.
Another unexpected finding was the wide separation between the AUCs for TIMP-2
and IGFBP7 compared to [TIMP-2]·[IGFBP7] for AKI. These differences were much
greater than what was observed in humans [2]. Interestingly, in the clinical study by
Kashani et al., TIMP-2 had a superior AUC compared to IGFBP7 in patients with
sepsis, whereas the opposite was seen in surgical patients [2]. We observed better
performance for TIMP-2 in this experimental model of sepsis (Fig. 1). These findings
suggest that sepsis-induced AKI may have a unique underlying pathobiology.
Finally, we observed that while TIMP-2 was a better performing marker for AKI, it
was a very poor predictor of mortality and IGFBP7 was better for this outcome (AUC
0.76 vs. 0.53); though not quite significant (p = 0.06) (Fig. 3). This uncoupling of
predictors of AKI and mortality was unexpected and may warrant further investigation.
Our study also showed that urine [TIMP-2]·[IGFBP7] was superior to NGAL. NGAL
derivation and validation studies were primarily performed in ischemic or nephrotoxic
AKI, while investigations of NGAL in septic AKI have demonstrated variable results
[21]. NGAL is known to be released by activated neutrophils and appears to be elevated
in sepsis, which may complicate its diagnostic value for AKI in patients with sepsis.
Our study also used RIFLE I/F AKI criteria (creatinine only) as the primary endpoint so
as to more closely model the clinical scenario in humans. Of note, we have previously
shown that in antibiotic-treated animals using this exact model, 1-week mortality for
RIFLE-F was 36.4 % [22]. This is remarkably similar to 40.3 % crude hospital mortality
reported for critically ill patients with KDIGO stage 3 AKI (using creatinine alone) [23]
or the 32.4 % covariate-adjusted hospital mortality for KDIGO stage 3 AKI (using both
creatinine and urine output) [13].
Our study has important limitations. As a secondary analysis, we were limited in
what time points were available. It would have been useful, for example, to have
measurements every 1–2 h. However, it is unlikely that we could have obtained this
frequency of monitoring in our rats even if we would have tried. Secondly, we chose a
relatively high severity model with substantial early mortality (40 % by day 2). It is not
known whether a less severe model would have resulted in similar or different results.
Finally, our model involved fluid resuscitation with saline in half of the animals, and
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indeed, the majority of animals reaching the AKI endpoint received saline. Therefore,
the exposure is “sepsis plus saline” rather than sepsis alone. However, this mirrors the
clinical reality in much of the world especially North America where sepsis patients are
invariably resuscitated with saline [24].
Conclusions
In conclusion, we have validated the [TIMP-2]·[IGFBP7] test in an experimental model
of sepsis-associated AKI using CLP. Our results establish the test in the preclinical
space.
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